The FirstTake Podcast – Does a paradigm shift in breast cancer beckon?

This week FirstWord Pharma PLUS editors Michael Flanagan, Virginia Li and Simon King discuss confirmation of positive top-line data for AstraZeneca and Daiichi Sankyo’s Enhertu in HER2 ‘low’ breast cancer, the implications stemming from Amicus Therapeutics’ decision to abort a gene-therapy spin out and whether GlaxoSmithKline and Sanofi’s long-awaited COVID-19 vaccine has arrived too late to make a meaningful impact on the pandemic.